Innovation in

ENGAGING GAMMA-DELTA T CELLS

to potently and precisely fight cancer

AT LAVA, WE ARE APPLYING OUR

EXPERTISE IN GAMMA-DELTA T CELL ENGAGERS

(TCEs) to transform cancer therapy. Our novel platform generates gamma-delta bispecific T cell engager (bsTCE) therapeutics that activate a unique and relatively abundant effector gamma-delta T cell subset called Vγ9Vδ2 (Vgamma9-Vdelta2) T cells. Our gamma-delta bsTCEs have demonstrated potent, specific Vg9Vd2 T cell activation and killing of patient-derived tumor cells in preclinical studies.  We expect that activation of adaptive immunity by our approach has the potential to provide durable immune responses with the potential of enhancing patient survival.

Learn More

Our Approach
bispecific gamma-delta T cell engagers
Our Pipeline
novel gamma-delta T cell engaging platform
Our Team
LAVA’s Leadership

// LAVA Therapeutics Provides Business Update and Reports Second Quarter Results » Full Release

// LAVA Therapeutics Announces Appointment of Amy Garabedian as General Counsel and Corporate Secretary » Full Release

// LAVA Therapeutics Announces Treatment of First Patient in Phase 1/2a Clinical Trial of LAVA-051 for Multiple Hematological Malignancies » Full Release